Phentermine
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Phentermine (2-methyl-1-phenylpropan-2-amine) is a synthetic stimulant of the phenethylamine class. It is a modified form of amphetamine, distinguished by reduced dopaminergic potency and lower abuse potential.[1] It releases norepinephrine — the brain's alertness signal — flooding appetite-control centers in the brain and producing a flat, sustained stimulation.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
The FDA approved phentermine in 1959 as a short-term appetite suppressant, one of the first amphetamine-class diet drugs to reach market.[3] Its reputation was nearly destroyed in 1997 when its combination partner, fenfluramine, was pulled for causing heart valve damage — phentermine itself was exonerated and remained available.[4] It remains the most prescribed obesity medication in the United States.
Subjective effects include appetite suppression, wakefulness, mild mood elevation, and low-level psychomotor activation. The experience is functional rather than euphoric — a sustained, flat stimulation without the rewarding rush of potent dopamine releasers.[5] Insomnia, dry mouth, elevated heart rate, and restlessness are characteristic unwanted effects.
Dependence liability is low — stopping abruptly does not produce cravings or amphetamine-like withdrawal.[6] The primary danger is cardiovascular: phentermine raises heart rate and blood pressure, and combining it with MAOIs can trigger a potentially fatal blood pressure crisis.[3] The drug has been on the market for over six decades, but its long-term cardiovascular safety profile remains incompletely characterized.[7]
History[edit]
Discovery
Phentermine was created in the early twentieth century by adding a second methyl group to the amphetamine scaffold, eliminating chirality and reducing dopaminergic activity.[1] The identity of the original synthesist is unconfirmed.citation needed The FDA approved it in 1959 as a short-term appetite suppressant, alongside other amphetamine-class diet drugs.[3]
The fen-phen crisis
In 1992, a landmark trial showed combining phentermine with fenfluramine produced far greater weight loss than placebo.[8] The combination — "fen-phen" — reached over 18 million prescriptions annually by 1996.[4] In 1997, fenfluramine was pulled after being linked to heart valve damage caused by its serotonergic mechanism; phentermine, which lacked that mechanism, was exonerated.[4][9]
Modern era
The EU banned phentermine in 2000–2001 while the US kept it on the market — a regulatory divergence that persists today. In 2012, the FDA approved phentermine combined with topiramate (Qsymia) for long-term weight management, the first new obesity drug in 13 years.[10] Phentermine monotherapy remains the most-prescribed obesity drug in the US, and the LEAP trial — the first long-term randomized controlled study of phentermine alone — is currently underway.[7]
The name "phentermine" compresses its chemical identity: phenyl-tertiary-butyl-amine. The compound's cultural image is inseparable from "fen-phen," which became synonymous with pharmaceutical scandal in the late 1990s — despite phentermine being exonerated. In clinical practice it is known by the brand name Adipex-P; in weight-loss communities by the shorthand "phen."
Chemistry[edit]
Structural class
Phentermine belongs to the amphetamine family of substituted phenethylamines.[1] Amphetamine has one methyl group at its central carbon; phentermine has two, eliminating the molecule's chirality and substantially reducing its dopaminergic potency while preserving norepinephrine-releasing activity.[2]
Molecular properties
| Molecular formula | C₁₀H₁₅N |
| Molecular weight | 149.23 g/mol |
Phentermine hydrochloride is a water-soluble white crystalline solid.[11] The free base is lipophilic enough to cross the blood–brain barrier readily.[12]
Pharmacology[edit]
Mechanism of action
Phentermine triggers the release of norepinephrine from nerve terminals, with weaker dopamine release and minimal serotonin activity.[2] That norepinephrine acts on appetite-control structures in the hypothalamus — the lateral hypothalamus and paraventricular nucleus — shifting the body toward satiety and reducing food intake.[13] The FDA describes its action as similar to amphetamine but less strong.[12][3]
At clinical doses, imaging studies in primates show no measurable dopamine release in the striatum — the brain's main reward center — whereas amphetamine at equivalent doses produces robust release.[5] This is why phentermine has lower abuse potential and is classified as Schedule IV rather than Schedule II.
Pharmacokinetics
Phentermine is nearly completely absorbed after oral dosing, with bioavailability approaching 100%.[11][3] The half-life ranges from 16 to 31 hours and varies substantially with urinary pH — acidic urine speeds elimination, alkaline urine prolongs it.[11] Most of the drug (62–85% of a dose) is excreted unchanged in urine, so drug interactions through liver enzyme competition are minimal.[11][12]
Neuroscience[edit]
Where it acts
Phentermine's primary target is the hypothalamus — the brain region that integrates hunger and fullness signals from hormones like leptin and ghrelin.[13] Released norepinephrine shifts this system toward satiety, reducing both the urge to start eating and the amount consumed.
In the brain's reward system, phentermine's footprint is minimal. Imaging in primates shows no measurable dopamine release in the striatum at clinical doses.[5] Indirect signals do reach the nucleus accumbens,[14] but this appears insufficient to drive compulsive use.
Tolerance and sensitisation
The appetite-suppressing effect fades within weeks of continuous use.[3] The mechanism is unknown — the leading candidates are downregulation and depletion of norepinephrine stores. Whether phentermine produces the structural brain changes seen with amphetamine has not been studied.
Several questions remain unanswered. The mechanism behind rapid anorectic tolerance is unknown. Whether phentermine produces lasting structural changes in reward-circuit neurons — as amphetamine does — has not been investigated, a question with direct implications for long-term use safety. The relationship between urinary pH variability, drug exposure, and tolerance development has never been studied.
Subjective Effects[edit]
Phentermine produces a mild, sustained stimulation with one defining feature: hunger disappears. The effect is background and functional — no rush, no euphoria, no perceptual change. The body feels alert and wakeful, the mind stays clear, and the drive to eat recedes throughout the day.
Compared to amphetamine, phentermine is notably flatter — no dopamine rush, no reward spike, with a qualitatively similar but lighter wakefulness profile. Relative to caffeine, it is a more potent appetite suppressant with a much longer duration and a greater cardiovascular load.
Effect Grid
At 15–37.5 mg oral, the full therapeutic profile emerges. Appetite suppression is pronounced — hunger signals are substantially blunted, and caloric intake decreases meaningfully. Wakefulness is sustained throughout the day, and mild cognitive euphoria or mood brightening may be present, though far less intense than with amphetamine. Focus enhancement and motivation enhancement are noticeable but modest.
Dry mouth is the most frequently reported physical effect. Stimulation is clear: elevated heart rate, mild blood pressure increase, and occasional restlessness or fidgetiness. Constipation occurs in a minority of users. Headache and trembling are possible but uncommon.
Insomnia is likely if the dose is taken after midday. This is the standard clinical range — effects last 8–14 hours subjectively, with residual wakefulness extending further due to the 16–31 hour half-life. Tolerance to the anorectic effect typically develops within a few weeks of continuous use.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dry mouth · Insomnia · Pupil dilation · Heart rate perception changes · Restlessness · Constipation · Dehydration sensation · Excessive sweating · Headache · Dizziness · Muscle tension · Nausea · Trembling · Bruxism
Restlessness · Constipation · Dehydration sensation · Excessive sweating · Headache · Dizziness · Muscle tension · Nausea · Trembling · Bruxism
Confusion
Disinhibition
Timeline
Initial absorption with minimal subjective awareness. A faint sense of alertness may emerge toward the end of this phase.
Rising sympathomimetic activation becomes noticeable. Appetite begins to diminish and wakefulness increases steadily. Heart rate may rise slightly.
Maximum anorectic and stimulant effects. Appetite suppression is pronounced, wakefulness is sustained, and dry mouth is common. Mild mood brightening may be present.
Sustained therapeutic effect at slightly reduced intensity. Appetite suppression is maintained and stimulation continues but feels less acute. Functional performance is preserved.
Gradual waning of stimulant effects. Appetite may partially return. Wakefulness persists but the driven quality diminishes.
Residual wakefulness and mild alertness persist due to the long plasma half-life (16–31 hours). Insomnia is possible if the dose was taken after midday.
⚠ Do not drive if experiencing dizziness or overstimulation.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- amphetamine · methamphetamine · MDMA
Toxicity
Acute toxicity
Overdose produces agitation, dangerously elevated body temperature, and high blood pressure.[11] Severe cases can progress to seizures, stroke, and coma. No human lethal dose has been establishedsafety citation needed — toxicity varies widely with tolerance, with a 150-fold range between symptomatic and survivable blood concentrations.[11]
Population data from Tennessee (2019–2022) found phentermine present in fatal overdose toxicology reports, but almost always alongside other substances — consistent with polydrug deaths rather than phentermine alone.[15]
For phentermine overdose: contact Poison Control (US: 1-800-222-1222). Treatment is supportive — airway stabilisation, heart rhythm monitoring, benzodiazepines for agitation and seizures, active cooling for dangerously elevated body temperature, IV fluids for muscle breakdown. Urinary acidification can accelerate elimination. Avoid beta-blockers alone — they may worsen high blood pressure through unopposed alpha-adrenergic stimulation.[11][3]
Cardiovascular toxicity
A case report describes pulmonary hypertension developing after just 5 weeks of phentermine monotherapy.[16] The fen-phen valvular disease was caused by fenfluramine's serotonergic mechanism — not phentermine.[4][9] Cardiovascular safety signals for phentermine and other anti-obesity drugs have been evaluated in FDA adverse event data.[17]
Phentermine is absolutely contraindicated in coronary artery disease, stroke, irregular heart rhythms, heart failure, and uncontrolled high blood pressure.[3]
Psychological risks
Psychosis is listed as a rare adverse effect on the FDA prescribing label.[3] At doses above the prescribed range or in predisposed individuals, phentermine can trigger paranoia, hallucinations, and delusional thinking.[12]
Risk factors include pre-existing psychotic disorders, bipolar disorder, concurrent stimulant use, and use above prescribed doses. The prescribing label contraindicates phentermine in "agitated states".[3]
Tolerance and dependence
Tolerance to appetite suppression and stimulant effects develops within weeks. Some tolerance was also documented over a 4-year combination trial.[18] The FDA label recommends stopping the drug rather than raising the dose when tolerance appears.[3]
Dependence liability is low. A study of 35 patients who stopped long-term phentermine abruptly found withdrawal scores no different from non-users — strikingly lower than amphetamine-dependent individuals — and cravings were entirely absent.[6] Phentermine produces recognisable stimulant-like effects in substance users but at lower intensity than methylphenidate.[19][20] Cross-tolerance with amphetamine, methamphetamine, and MDMA is probable based on shared mechanism but has not been directly studied.
Drug interactions
MAOI interaction (absolute contraindication): MAOIs block the breakdown of norepinephrine; combined with phentermine's catecholamine release, this can trigger a potentially fatal blood pressure spike.[3] A 14-day washout is required before use.
SSRI/SNRI interaction: serotonin syndrome — a potentially life-threatening overheating and seizure response — is a theoretical risk. A survey of 1,174 patients taking phentermine with SSRIs found zero cases,[21] but a 2025 case report documented multi-organ injury from an anti-obesity and antidepressant combination.[22] Monitoring is warranted.
Other stimulants: Combining phentermine with other stimulants (amphetamine, MDMA, cocaine) would be expected to produce additive cardiovascular strain.safety citation needed
Blood pressure medications: Phentermine may reduce the effectiveness of blood-pressure-lowering drugs through pharmacological antagonism.[3] Conversely, phentermine-induced weight loss can lower systolic blood pressure by 7.5–11.8 mmHg, potentially requiring dose reduction of existing medications.[23]
Insulin and diabetes medications: Weight loss from phentermine improves insulin sensitivity, which may reduce insulin requirements and risk dangerously low blood sugar.[3]
pH-modifying agents: Urinary acidifiers (ammonium chloride) speed phentermine elimination; urinary alkalinisers (sodium bicarbonate) extend its half-life.[11]
Fenfluramine (historical): Phentermine did not significantly amplify fenfluramine-induced serotonin depletion in mouse brain at doses far exceeding clinical use.[24]
Drug testing: Phentermine produces positive results on standard amphetamine urine drug screens. Confirmatory GC-MS or LC-MS/MS testing is required to distinguish it from methamphetamine or amphetamine.[12] Detection window is approximately 2–4 days at standard doses.
Contraindications
The following contraindications are derived from the FDA prescribing information[3]:
Absolute contraindications:
- Concurrent or recent MAOI use (within 14 days)
- Cardiovascular disease: coronary artery disease, stroke, irregular heart rhythms, heart failure, uncontrolled high blood pressure
- Overactive thyroid: excess thyroid hormone amplifies cardiovascular stimulant effects
- Glaucoma: pupil dilation can trigger acute angle-closure crisis
- Agitated states: stimulation may worsen psychiatric instability
- History of drug abuse: phentermine produces recognisable stimulant effects in substance users[19]
- Known allergy to sympathomimetic amines
Pregnancy: The phentermine/topiramate combination (Qsymia) is absolutely contraindicated in pregnancy due to topiramate's risk of birth defects, enforced through a mandatory safety programme.[10] No controlled data exist for phentermine alone in pregnancy; it is presumed unsafe.safety citation needed
Nursing: Whether phentermine passes into breast milk has not been determined; use during breastfeeding is contraindicated.[3]
Harm Reduction[edit]
Forms & Identification
Phentermine is a prescription drug available in standardized formulations: Adipex-P (37.5 mg tablets and capsules) and Lomaira (8 mg tablets).[12] A slower-absorbing resin formulation (Ionamin) has been discontinued. The main concern is product authenticity — counterfeit or diverted tablets circulate online and may contain wrong doses, substituted ingredients, or no active drug at all.
Guidelines
- Take phentermine in the morning to reduce insomnia risk
- Maintain adequate fluid intake — stimulant effects and appetite suppression can mask dehydration
- Eat regular meals despite reduced appetite; prolonged caloric restriction without nutritional planning carries its own health risks
- Do not increase the dose if appetite suppression weakens — tolerance is expected and dose escalation increases cardiovascular risk without restoring effectiveness
- Avoid caffeine and other stimulants, which compound cardiovascular strain
- Monitor resting heart rate and blood pressure periodically, especially during the first weeks of use
- Do not crush or chew extended-release formulations
Set & Setting
Phentermine is a sustained stimulant with a half-life of 16–31 hours. Morning dosing is standard practice — taking it after midday substantially increases insomnia risk. Effects are mild and functional; no special preparation is needed beyond planning for reduced appetite and ensuring adequate hydration throughout the day.
Aftercare & integration. After stopping phentermine — whether at the end of a prescribed course or due to tolerance — appetite returns, often intensely. Hunger signals suppressed during treatment come back. Planning nutritional strategies before discontinuation helps prevent rapid weight regain.
Sleep disruption may linger for several days after the last dose, given the drug's long half-life. Maintaining consistent sleep schedules and avoiding caffeine during the washout period supports recovery. Fatigue and low energy in the first week off phentermine are common and typically self-limiting.
Recovery & Support
Phentermine dependence is uncommon, but psychological reliance on appetite suppression can develop — particularly when used as the sole weight-management strategy without dietary or behavioural change. If stopping feels unmanageable or doses have been escalated beyond prescription, professional support is appropriate.
Resources include prescribing physicians (who can supervise tapering), registered dietitians for nutritional transition planning, and SAMHSA's National Helpline (1-800-662-4357) for substance use concerns. Cognitive behavioural therapy has established efficacy for both weight management and stimulant use disorders.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: chest pain, severe headache, rapid or irregular heartbeat, confusion, seizures, body temperature hot to the touch through clothing, or loss of consciousness. These distinguish a medical emergency from ordinary stimulant side effects like mild restlessness or dry mouth.
Immediate steps:
- 1. Call emergency services (911 in the US)
- 2. Do not administer more phentermine or other stimulants
- 3. If the person is conscious and overheating, move to a cool environment and apply cool water to skin
- 4. If unconscious but breathing, place in the recovery position
- 5. Do not induce vomiting
- 6. Do not administer beta-blockers — they may worsen the situation
What to tell the dispatcher: The substance (phentermine), approximate dose and time taken, any other medications or substances used, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Phentermine has been continuously approved in the United States since 1959 but was banned or withdrawn across most of Europe in 2000–2001, a regulatory divergence that persists today.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | FDA-approved 1959; phentermine monotherapy (Adipex-P, Lomaira) and combination (Qsymia) both marketed. Qsymia subject to REMS.[10] |
| Canada | Schedule IV (CDSA) | Available by prescription. |
| Australia | Approved (TGA) | Marketed as Duromine (phentermine resin capsules); prescription required. |
| New Zealand | Approved | Available as Duromine; prescription required. |
| United Kingdom | Withdrawn | MHRA withdrew marketing authorisation circa 2000.[25] |
| European Union | Banned | European Commission decision March 2000; effective April 2001. EMA rejected PHEN/TPM (Qsiva) in 2012 and 2013.[25] |
| Germany | Withdrawn | Marketing authorisation withdrawn as part of EU-wide action.[12] |
| Sweden | Banned | Controlled substance; not marketed.[25] |
| Turkey | Banned | Not available.[25] |
Legal status changes frequently and varies by jurisdiction. This article is not legal advice. Verify current status with local authorities before obtaining or using phentermine.
Drug testing: Phentermine produces positive results on standard amphetamine immunoassay urine drug screens. Confirmatory testing (GC-MS or LC-MS/MS) is required to distinguish it from methamphetamine or amphetamine.[12] Prescription holders should disclose phentermine use to drug testing facilities to avoid false-positive interpretation.
Phentermine monotherapy does not carry a REMS requirement in the United States.[10] The REMS programme applies only to Qsymia (phentermine/topiramate ER), designed to prevent pregnancy exposure to topiramate.
references
- [1]
- [2] ^abcRothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin — Synapse PMID:11071707
- [3]
- [4] ^abcdConnolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine — New England Journal of Medicine PMID:9271479
- [5] ^abcAlexander M, Rothman RB, Baumann MH, et al. (2005) Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis — Synapse PMID:15729739
- [6] ^abHendricks EJ, Greenway FL (2011) A study of abrupt phentermine cessation in patients in a weight management program — American Journal of Therapeutics doi:10.1097/mjt.0b013e3181d070d7